Stockscreener 앱 받기
4.26
0.47%
-0.02
시간 외 거래:
4.34
0.08
+1.88%
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc.NUVB - PR Newswire
Nuvation Bio (NYSE:NUVB) Expands Cancer Story With Strong Update Nyse Composite Today - Kalkine Media
New Highs: Will Nuvation Bio Inc outperform the market in YEARWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio ... - Bluefield Daily Telegraph
Nuvation Bio set to present efficacy and safety results of ROS1 inhibitor at AACR26 - Traders Union
Lung cancer drug IBTROZI keeps responses going over 4 years in trial - Stock Titan
Nuvation Bio (NUVB) Is Down 6.1% After Eisai Deal And Stock Shelf Filing Has The Bull Case Changed? - simplywall.st
Nuvation Bio Inc. (NUVB) announces exclusive licensing agreement with Eisai to expand global reach of taletrectinib - MSN
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - marketscreener.com
RBC Capital Lifts PT on Nuvation Bio (NUVB) to $13 From $12 – Here’s Why - Insider Monkey
15 Best Penny Stocks to Buy According to Reddit - Insider Monkey
NUVB Stock Price, Quote & Chart | NUVATION BIO INC (NYSE:NUVB) - ChartMill
Nuvation Bio (NUVB) Q4 2025 Earnings Transcript - AOL.com
A Look At Nuvation Bio (NUVB) Valuation After Its 2025 Results Show Revenue Growth And A Narrowed Net Loss - simplywall.st
NUVB: IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications - TradingView
NUVB: Ibtrozi leads ROS1 market growth with superior efficacy and expanding first-line adoption - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPL - GlobeNewswire Inc.
Aug Setups: Will Nuvation Bio Inc outperform the market in YEARLayoff News & Daily Profit Focused Screening - baoquankhu1.vn
Nuvation Bio Earnings Call: IBTROZI Surge, Long Runway - The Globe and Mail
Nuvation Bio Faces Weak Start with 18.49% Gap Down Amid Market Concerns - Markets Mojo
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm – Company Announcement - Financial Times
Nuvation Bio Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
Citigroup Inc. Has $3.42 Million Stake in Nuvation Bio Inc. $NUVB - MarketBeat
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
Nuvation Bio Stock Hits Day Low of $4.16 Amid Price Pressure - Markets Mojo
Nuvation Bio Hits Day High with Strong 8.72% Intraday Surge - Markets Mojo
Q1 EPS Estimates for Nuvation Bio Reduced by HC Wainwright - MarketBeat
Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks - The Globe and Mail
10 Best Low Cost Stocks to Buy Under $5 - Insider Monkey
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Bitget
NUVB: First-line patient growth, strong efficacy, and robust cash position drive positive outlook - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress - Yahoo Finance
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Malaysian Reserve
Nuvation Bio Inc. $NUVB is Aisling Capital Management LP's 4th Largest Position - MarketBeat
NUVB-WT Nuvation Bio NYSE down 27% pre-market after Q4: cash runway focus - Meyka
Nuvation Bio (NUVB) Q4 Revenue Surge Tests Bullish Growth Narrative Against Ongoing Losses - simplywall.st
Nuvation Bio (NUVB) awards stock options and RSUs to company officer - Stock Titan
Director Xiangmin Cui awarded 74,813 Nuvation Bio (NUVB) stock options - Stock Titan
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy - The Globe and Mail
Deep Dive Into Nuvation Bio Stock: Analyst Perspectives (7 Ratings) - Benzinga
UBS Group Lowers Nuvation Bio (NYSE:NUVB) Price Target to $7.00 - MarketBeat
Nuvation Bio (NUVB) Analyst Rating Update: UBS Lowers Price Targ - GuruFocus
NUVB Crosses Below Key Moving Average Level - Nasdaq
Nuvation Bio (NYSE:NUVB) Shares Gap DownShould You Sell? - MarketBeat
NUVB: RBC Capital Raises Price Target for Nuvation Bio | NUVB St - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
UBS Adjusts Price Target on Nuvation Bio to $7 From $10, Maintains Neutral Rating - marketscreener.com
Nuvation Bio price target raised to $13 from $12 at RBC Capital - TipRanks
1.20%
0.06%
자본화:
|
볼륨(24시간):